

DIRECTORS AND SENIOR MANAGEMENT

BOARD OF DIRECTORS

Upon the [REDACTED], our Board will comprise nine Directors, including six executive Directors and three independent non-executive Directors^(note). Our Directors serve a term of [three] years and may be re-elected for successive re-appointments.

The table below sets out certain information of our Directors.

Name	Age	Position	Time of appointment as Director	Time of joining our Group	Major responsibilities	Relationship with other Directors and senior management
Executive Directors						
Dr. CHEN Yuxin (陳育新)	54	President, Chairman of the Board and Chief Executive Officer	April 2009	April 2009	Responsible for the overall strategic planning, business management and corporate governance of our Group	None
Mr. ZHANG Wendong (張文棟)	52	Vice President and Secretary of the Board	December 2025	July 2020	Responsible for securities-related affairs and financing	None
Mr. ZHOU Peng (周鵬)	44	Head of Finance	December 2025	May 2018	Responsible for finance department	None
Ms. CHEN Mingxia (陳明俠)	51	Vice President	December 2025	May 2009	Responsible for clinical research and development of new drugs, overseeing the clinical medicine department, pharmacovigilance department, registration department	None
Mr. FENG Shangbin (馮尚斌)	50	Head of Quality Department	December 2025	July 2019	Responsible for quality department	None
Mr. DONG Hu (董虎)	39	Head of Clinical Medicine Department	December 2025	June 2019	Responsible for clinical medicine department	None
Independent Non-executive Directors						
Dr. SHI Wei (施維)	66	Independent Non-executive Director	December 2025	December 2025	Responsible for providing independent opinion and judgment to our Board	None
Mr. QIAN Junfeng (錢俊峰)	47	Independent Non-executive Director	December 2025	December 2025	Responsible for providing independent opinion and judgment to our Board	None
Dr. XU Aimin (徐愛民)	58	Independent Non-executive Director	December 2025	December 2025	Responsible for providing independent opinion and judgment to our Board	None

Note: Mr. Chen Zhaoxin (陳照新), Ms. Ouyang Jinyu (歐陽謹瑜), Ms. Shu Wanting (舒婉婷), Ms. Gu Fei (顧菲), Mr. Shen Guangping (沈廣平), and Mr. Chen Zhuxi (陳築熙) were directors of our Company (the “Outgoing Directors”) in the 12 months prior to the Latest Practicable Date, all of whom had already resigned on December 25, 2025, and had held non-executive roles and had not been involved in the day to day operations of the Company during his/ her tenure. Save for Mr. Chen Zhuxi who voluntarily departed due to the pre-[REDACTED] investor which he represented (i.e. Major Special Fund) no longer held any shares in the Company, all other Outgoing Directors resigned voluntarily upon re-election of the Board at our Company’s conversion into a joint stock company with limited liability, in order to facilitate the reorganization of the Board for the [REDACTED]. None of the Outgoing Director has any disputes and/or disagreements with the Group, and there are no other matters in respect of their resignations that should be brought to the Stock Exchange’s attention.

DIRECTORS AND SENIOR MANAGEMENT

Executive Directors

Dr. CHEN Yuxin (陳育新), aged 54, is our executive Director, president, chief executive officer, and the chairman of the Board. He is primarily responsible for the overall strategic planning, business management and corporate governance of our Group. As chairman of the Board, Dr. Chen focuses on high-level governance, board supervision, and the review and approval of top-level corporate policies and budgets. As president, he assumes a regulatory-focused role, taking direct accountability for ensuring compliance of all departments, the provision of resources to guarantee independent quality controls, in particular, the strict compliance with GMP, GVP, and environmental safety regulations. As chief executive officer, Dr. Chen oversees production and operation management, organises and implements the annual business plan and investment proposals, and bridges governance and operations by spearheading the Group’s macro strategic planning, driving business development, financial and commercial performance. Dr. Chen was appointed as our Director since April 2009, and will be re-designated as an executive Director upon [REDACTED].

Dr. Chen has also been serving as the director and chief executive officer of Nanjing Denovo since May 2020, the director and general manager of Jiangsu Putai since July 2020, the director of Wuxi Ruiyi since August 2020, and the director and general manager of Hangzhou Fuertai since November 2024. He has also been the executive director of Changchun ProteLight since March 2007. Dr. Chen also has been serving as a director in each of our other subsidiaries.

From March 2007 to November 2018, Dr. Chen was a professor, doctoral supervisor, and academic leader at the key laboratory of molecular enzymology and engineering of the ministry of education at Jilin University* (吉林大學), the PRC. His international research experience includes a postdoctoral fellowship in the department of biochemistry and molecular genetics at the University of Colorado health sciences center, the U.S., from March 2005 to February 2007. Earlier in his career, he worked as a biochemistry teaching assistant in the department of biochemistry at the faculty of medicine, University of Alberta, Canada, from September 2000 to July 2001.

Dr. Chen obtained his bachelor’s degree in biology from Northeast Normal University* (東北師範大學), the PRC, in July 1995, and obtained his master’s degree in biochemistry from Jilin University* (吉林大學), the PRC in August 1998. After that, he obtained a doctor of philosophy in biochemistry from the faculty of medicine, University of Alberta, Canada, in March 2005. Dr. Chen also conducted postdoctoral research in the department of biochemistry and molecular genetics at the University of Colorado, the U.S., during 2005 to 2007.

Dr. Chen was awarded the title of 2025 Forbes China Pioneer Innovators in Industry Development* (2025福布斯中國行業發展領創者) by Forbes China in March 2025. In December 2021, he was honored with the Outstanding Standing Committee Member (10th Term)* (第十屆優秀常執委) award by the Jiangyin Federation of Industry and Commerce* (江陰市工商業聯合會) and received the title of May Day Labor Model of Wuxi City* (無錫市五一勞動模範). In April 2020, he was granted the Jiangsu Province May Day Labor Honorary Medal* (江蘇省五一勞動榮譽獎章). In July 2018, he received the Outstanding Contribution Award for Peptide Application* (多肽應用傑出貢獻獎) at the 15th Chinese International Peptide Symposium* (第十五屆中國國際多肽學術會議).

Mr. ZHANG Wendong (張文棟) (“Mr. Zhang”), aged 52, is our executive Director, vice president and secretary of the Board. He is primarily in charge of securities-related affairs and financing of our Group. Mr. Zhang was appointed as our Director in December 2025, and will be re-designated as an executive Director upon [REDACTED].

Mr. Zhang served as securities affairs representative at Jiangsu Fasten Co., Ltd.* (江蘇法爾勝股份有限公司) (“**Jiangsu Fasten**”), a company listed on the Shenzhen Stock Exchange (Stock Code: 000890), from January 1998 to January 2008, and was primarily responsible for securities-related operations. Subsequently, from January 2008 to April 2014, Mr. Zhang was the board secretary at Jiangsu Fasten and was responsible for overseeing securities-related operations and investment activities. He was then the deputy general manager and board secretary at Jiangsu Fasten from April 2014 to March 2018, and the executive deputy general manager at Jiangsu Fasten from March 2018 to July 2020. Mr. Zhang was then an independent director at Vtron Group Co., Ltd.* (威創集團股份有限

DIRECTORS AND SENIOR MANAGEMENT

公司) from June 2023 to January 2025. From June 2023 to June 2026, he was also an independent director at Zhongnan Red Culture Group Co., Ltd.* (中南紅文化集團股份有限公司), a company listed on the Shenzhen Stock Exchange (Stock Code: 002445).

Mr. Zhang obtained a bachelor’s degree in metallic materials and heat treatment from Southeast University* (東南大學), the PRC, in June 1996 and obtained his master’s degree in business administration from Jiangsu University* (江蘇大學), the PRC, in December 2014, respectively.

Mr. ZHOU Peng (周鵬) (“Mr. Zhou”), aged 44, is our executive Director and head of finance. He is primarily responsible for overseeing financial affairs of our Group. Mr. Zhou was appointed as our Director in December 2025, and will be re-designated as an executive Director upon [REDACTED].

Mr. Zhou has extensive experience in corporate finance and governance. From September 2012 to April 2018, Mr. Zhou served as head of finance of HLA Group Corp., Ltd.* (海瀾之家集團股份有限公司) (a company listed on the Shanghai Stock Exchange (stock code: 600398.SH)). Prior to that, he worked at Bekaert (China) Technology Research & Development Co., Ltd.* (貝卡爾特(中國)技術研發有限公司) from January 2009 to September 2012. From September 2007 to January 2009, he also worked at Jiangyin Rhenoflex New Materials Co., Ltd.* (江陰雷諾菲克斯新材料有限公司). Earlier in his career, Mr. Zhou worked at Jiangyin Huaming Electric Equipment Co., Ltd.* (江陰華明電氣設備有限公司) from July 2004 to May 2007.

Mr. Zhou has been a member of the Jiangsu Institute of Certified Public Accountant (江蘇省註冊會計師協會) since April 2017, and an intermediate accountant (中級會計) recognized by the Department of Human Resources and Social Security of Jiangsu Province* (江蘇省人力資源和社會保障廳) since August 2010. Mr. Zhou obtained a bachelor’s degree in management from Changsha University of Science and Technology* (長沙理工大學), the PRC, in June 2004.

Ms. CHEN Mingxia (陳明俠) (“Ms. Chen”), aged 51, is our executive Director and vice president. She is mainly responsible for clinical research and development of new drugs, overseeing the clinical medicine department, pharmacovigilance department, registration department of our Group. Ms. Chen served as the R&D director of Changchun ProteLight from May 2009 to December 2019. Ms. Chen was appointed as our Director in December 2025, and will be re-designated as an executive Director upon [REDACTED].

Ms. Chen has been serving as an adjunct graduate cooperation supervisor at Jilin University* (吉林大學) since October 2024. Prior to that, Ms. Chen served as laboratory supervisor and president’s assistant at Beijing Huanfo Pharmaceutical Research Center Co., Ltd. (北京華安佛醫藥研究中心有限公司) from May 2005 to April 2009; she served as the chief pharmacist and manager at Joinn Laboratories (China) Co., Ltd.* (北京昭衍新藥研究中心股份有限公司) (a company listed both on the Shanghai Stock Exchange (stock code: 603127.SH) and the Hong Kong Stock Exchange (stock code: 06127.HK)) from July 2002 to May 2005.

Ms. Chen completed her vocational undergraduate studies in clinical medicine from Norman Bethune University of Medical Science* (白求恩醫科大學), the PRC, in July 1996. She received her master’s degree in pharmacology from Jilin University* (吉林大學), the PRC, in June 2022. In 2024, Ms. Chen was nominated as a leader of the Wuxi City “Taihu Talent Plan” Innovation and Leadership Talent Team* (無錫市“太湖人才計劃”創新領軍人才團隊帶頭人).

Mr. FENG Shangbin (馮尚斌) (“Mr. Feng”), aged 50, is our executive Director and head of our quality department. He is primarily responsible for overseeing the daily operations and management of the quality department of our Group. Mr. Feng was appointed as our Director in December 2025, and will be re-designated as an executive Director upon [REDACTED]. Mr. Feng is a licensed pharmacist.

With over two decades of extensive professional experience, Mr. Feng has built a career spanning several well-known domestic and international pharmaceutical and biotechnology companies, demonstrating profound expertise and exceptional leadership. Prior to joining our Company, he served as deputy general manager of quality at Jiangsu Coben Pharma Co., Ltd.* (江蘇科本藥業有限公司) from May to July 2019. From April 2018 to May 2019, he held the position of quality manager at Jiangsu Lingyun Pharmaceutical Co., Ltd.* (江蘇凌雲藥業股份有限公司). Prior to that Mr. Feng worked as senior quality manager at CoronBio Biotechnology (Taicang) Co., Ltd.* (中美冠科生物技術(太倉)有限公司) from December 2015 to March 2018. From October 2009 to October 2015, he was

DIRECTORS AND SENIOR MANAGEMENT

employed as quality manager at Wuxi Jida Pharmaceutical Co., Ltd.* (無錫積大製藥有限公司). Between October 2007 and October 2009, Mr. Feng worked at Yessamin (Nantong) Healthcare Co., Ltd.* (耶賽明(南通)保健食品有限公司). Prior to that, he worked at the Wuxi branch of AstraZeneca Pharmaceutical Co., Ltd.* (阿斯利康製藥有限公司無錫辦事處) from April 2003 to October 2007. Previously, Mr. Feng worked at Wuxi No.7 Pharmaceutical Co., Ltd.* (無錫市第七製藥有限公司) from July 1999 to March 2003.

Mr. Feng obtained his master’s degree in chemical engineering from Changzhou University* (常州大學), the PRC, in July 2015. He obtained his bachelor’s degree in science (pharmaceutical formulation) from China Pharmaceutical University* (中國藥科大學).

Mr. DONG Hu (董虎) (“Mr. Dong”), aged 39, is our executive Director and head of our clinical medical department. He is primarily responsible for the daily operations and administration of the clinical medicine department of our Group. Mr. Dong was appointed as our Director in December 2025, and will be re-designated as an executive Director upon [REDACTED].

Mr. Dong possesses extensive experience in drug research and development. Prior to joining our Company, he worked at Yangtze River Pharmaceutical Group* (揚子江藥業集團有限公司) from July 2015 to May 2019 and was appointed as a clinical project manager and clinical leader in March 2017. From July 2012 to May 2015, he worked at Jiangsu Ascentage Pharma Corporation Limited* (江蘇亞盛醫藥開發有限公司) (a company listed on the Hong Kong Stock Exchange (stock code: 06855.HK)).

Mr. Dong obtained his bachelor’s degree in bioengineering from China Pharmaceutical University* (中國藥科大學), the PRC, in 2008. He received his master’s degree in physiology from Wenzhou Medical University* (溫州醫科大學), the PRC, in 2012.

Mr. Dong was also selected as a core member of the Entrepreneurship Leading Team under the 2021 Wuxi Taihu Talent Program* (2021年無錫市“太湖人才計劃”創業領軍團隊), a prestigious recognition of his innovative capabilities and leadership potential.

Independent Non-executive Directors

Dr. SHI Wei (施維) (“Dr. Shi”), aged 66, is an independent non-executive director of our Company. He is primarily responsible for providing independent opinion and judgment to our Board. Dr. Shi was appointed as an independent Director in December 2025, and will be redesignated as an independent non-executive Director from the [REDACTED].

Dr. Shi has been appointed as a director of Changchun BCBT Biotechnology Co.* (長春百克生物科技股份有限公司) (a company listed on the Shanghai Stock Exchange (stock code: 688276.SH)), since 2024. He had also served as a director of Tonghua Dongbao Pharmaceutical Co., Ltd.* (通化東寶藥業股份有限公司) (a company listed on the Shanghai Stock Exchange (stock code: 600867.SH)), from 2015 to 2021.

Dr. Shi has long been dedicated to research and teaching in the fields of molecular biology, immunology, and tumor immunology, possessing a profound academic background and extensive research experience. From September 2006 to September 2024, he served as professor at the Key Laboratory of Molecular Enzyme Engineering, Ministry of Education, Jilin University* (吉林大學分子酶工程學研究室教育部重點實驗室), the PRC. From April 2001 to March 2005, Dr. Shi was granted a CIHR Fellowship funded by the Canadian Institutes of Health Research (CIHR) at the Ontario Cancer Institute in Canada. Between April 1999 and March 2001, he was appointed as a foreign special researcher under the Japan Society for the Promotion of Science (JSPS) in the molecular immunology laboratory at the Institute of Microbial Diseases, the University of Osaka, Japan. From October 1993 to March 1999, he worked as a researcher in the immunology laboratory at the Institute of Cellular Engineering, the University of Osaka, Japan. Previously, Dr. Shi served as an assistant researcher in the molecular genetics laboratory at the Institute of Biological Engineering, Academy of Military Medical Sciences, Beijing* (北京軍事醫學科學院生物工程研究所).

Dr. Shi was awarded the Outstanding Overseas Returned Talent Award of Jilin Province* (吉林省優秀海外歸國人才優秀獎) in December 17, 2014 by Jilin Association for Science and Technology* (吉林省科學技術協會).

DIRECTORS AND SENIOR MANAGEMENT

Dr. Shi obtained his bachelor’s degree in biochemistry from Jilin University* (吉林大學), the PRC, in December 1982. He received his master’s degree in medicine from PLA Military Medical College of Continuing Education* (北京解放軍軍醫進修學院), the PRC, in July 1988. In March 1999, he earned his doctor of philosophy in medicine (immunology) from the University of Osaka, Japan.

Mr. QIAN Junfeng (錢俊峰) (“Mr. Qian”), aged 47, is an independent non-executive director of our Company. He is primarily responsible for providing independent opinion and judgment to our Board. Mr. Qian was appointed as an independent Director in December 2025, and will be redesignated as an independent non-executive Director from the [REDACTED].

Mr. Qian is an experienced accountant with extensive practical expertise in auditing, particularly in the audit of listed companies. He obtained Chinese Certified Public Accountant (CICPA) certificate in 2009. Since December 2006, he has been working at Tianheng Certified Public Accountants (Special General Partnership)* (天衡會計師事務所(特殊普通合夥)) and has been serving as a partner since August 2018 and as a partner and head of audit department since July 2025. In 2002, Mr. Qian served as a staff member at the Securities Investment Department of Jiangsu Zongyi Co., Ltd. (江蘇綜藝股份有限公司) (stock code: 600770. SH). From April 2003 to November 2006, he worked at Panda Group Co., Ltd.* (熊貓集團有限公司).

Mr. Qian obtained his bachelor’s degree in investment economics from Nanjing University* (南京大學), the PRC, in June 2001.

Dr. XU Aimin (徐愛民) (“Dr. Xu”), aged 58, is an independent non-executive director of our Company. He is primarily responsible for providing independent opinion and judgment to our Board. Dr. Xu was appointed as an independent Director in December 2025, and will be redesignated as an independent non-executive Director from the [REDACTED].

Dr. Xu has extensive academic and research experience in the biomedical field. Since December 2024, he has been serving as the director of the Guangdong-Hong Kong Joint Laboratory of Metabolic Medicine* (粵港代謝醫學聯合實驗室). Since September 2024, he has held the position of Rosie Young Endowed Professor at the University of Hong Kong. Dr. Xu Aimin had been working at Li Ka Shing Faculty of Medicine, The University of Hong Kong between 2002 and June 2007, during which he was mainly responsible for conducting research in, among others, the field of adiponectin. From July 2007 to May 2011, Dr. Xu was an associate professor specializing in medicine, pharmacology and pharmacy at the University of Hong Kong. He was then a professor at the University of Hong Kong from June 2011 to April 2018. Since July 2013, Dr. Xu was also the director of the State Key Laboratory of Pharmaceutical Biotechnology at the University of Hong Kong. Since May 2018, Dr. Xu has been a chair professor in the department of medicine and the department of pharmacology and pharmacy at the University of Hong Kong. Previously, Dr. Xu has been a director of the Hong Kong Institute of Metabolic Medicine.

Dr. Xu obtained his bachelor’s degree in medicine from Anhui Medical University* (安徽醫科大學), the PRC in June 1989. Subsequently, he obtained his doctor of philosophy in Biological Sciences from the University of Auckland, New Zealand, in May 2020, and then conducted postdoctoral research in molecular medicine at the same university from November 1999 to July 2002.

In 2025, Dr. Xu and his team received the Gold Medal at the International Exhibition of Inventions of Geneva, awarded by the Swiss Federal Government and the World Intellectual Property Organization. This same honor was also conferred upon him and his team in 2019. Furthermore, in 2024, he was awarded the National Natural Scientist Award (Second Class)* (國家自然科學獎(二等)) by the State Council of the People’s Republic of China* (中華人民共和國國務院). In 2021, he received the National Science and Technology Progress Award (Second Class)* (國家科技進步獎(二等)) from the State Council of the People’s Republic of China* (中華人民共和國國務院). Additionally, in 2019, he was granted the Medical Science and Technology Award (Second Class)* (中華醫學會醫學科技獎(二等)) by the Chinese Medical Association* (中華醫學會). In 2017, he was honored with the Guangdong Province Science and Technology Award (First Class)* (廣東省科學技術一等獎) by the Department of Science and Technology of Guangdong Province* (廣東省科技廳). In 2016, he received the Croucher Senior Research Fellowship from the Croucher Foundation in Hong Kong.

DIRECTORS AND SENIOR MANAGEMENT

OTHER INFORMATION IN RELATION TO OUR DIRECTORS

Each of the independent non-executive Directors confirms (i) his/her independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Listing Rules, (ii) that he/she had no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person of the Company under the Listing Rules as of the Latest Practicable Date, and (iii) that there are no other factors that may affect his/her independence at the time of his/her appointment.

Save as disclosed in this Document, as of the Latest Practicable Date, (i) each of the Directors and members of senior management did not hold any other positions in our Group, (ii) none of our Directors had any other relationship with any Directors, senior management or Substantial Shareholders of our Company; (iii) none of our Directors held any directorship in any other listed companies in the three years immediately prior to the date of this Document; and (iv) none of our Directors had interests in business, which competes or is likely to compete, either directly or indirectly with our business, which would require disclosure under Rule 8.10 of the Listing Rules.

Save as disclosed in this Document, to the best knowledge, information and belief of our Directors having made all reasonable enquiries, there was no other matter with respect to the appointment of our Directors that needs to be brought to the attention of the Shareholders and there was no information relating to our Directors that is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules as of the Latest Practicable Date. For the Directors’ interests in the Shares within the meaning of Part XV of the SFO, see “Appendix V — Statutory and General Information.”

Rule 3.09D of the Listing Rules

Each of our Directors confirms that he or she (i) has obtained the legal advice referred to under Rule 3.09D of the Listing Rules on January 14, 2026, and (ii) understands his or her obligations as a director of a [REDACTED] company under the Listing Rules.

SENIOR MANAGEMENT

The following table sets forth certain information of the senior management of our Group:

Name	Age	Position	Principal roles and responsibilities	Time of joining our Group	Time of appointment as Senior Management	Relationship with other Directors and senior management
Dr. CHEN Yuxin (陳育新).	54	President and Chief Executive Officer	Responsible for the overall strategic planning, business management and corporate governance of our Group	April 2009	April 2009	None
Ms. CHEN Mingxia (陳明俠).	51	Vice President	Responsible for clinical research and development of new drugs, overseeing the clinical medicine department, pharmacovigilance department, registration department	May 2009	May 2009	None
Mr. ZHANG Wendong (張文棟).	52	Vice President and Secretary of the Board	Responsible for securities-related affairs and financing	July 2020	July 2020	None
Mr. ZHOU Peng (周鵬).	44	Head of Finance	Responsible for financial planning, budgeting and cashflow management	May 2018	May 2018	None

DIRECTORS AND SENIOR MANAGEMENT

Name	Age	Position	Principal roles and responsibilities	Time of joining our Group	Time of appointment as Senior Management	Relationship with other Directors and senior management
Dr. ZHU Xu (諸旭)	48	Vice President	Responsible for drug discovery, non-clinical/pharmaceutical research and development, and overseeing the chemical drug R&D department, biopharmaceutical department, pharmacology and toxicology department, pharmaceutical analysis department, and pharmaceutical formulation department	January 2023	January 2023	None

Dr. CHEN, aged 54, was appointed as our president and chief executive officer in March 2009. For details of his biography, please see “— Board of Directors” above.

Ms. CHEN Mingxia (陳明俠), aged 51, was appointed as our vice president in May 2009. For details of her biography, please see “— Board of Directors” above.

Mr. ZHANG Wendong (張文棟), aged 52, was appointed as our vice president and secretary of the Board in July 2020. For details of his biography, please see “— Board of Directors” above.

Mr. ZHOU Peng (周鵬), aged 44, was appointed as our head of finance in May 2018. For details of his biography, please see “— Board of Directors” above.

Mr. ZHU Xu (諸旭) (“Mr. Zhu”), aged 48, is our vice president. He is primarily responsible for drug discovery, non-clinical/pharmaceutical research and development, and overseeing the chemical drug R&D department, biopharmaceutical department, pharmacology and toxicology department, pharmaceutical analysis department, and pharmaceutical formulation department.

Mr. Zhu possesses extensive work experience in formulating R&D strategies related to drugs for oncology, autoimmune diseases, central nervous system disorders, rare diseases, and other therapeutic areas. Mr. Zhu joined Axter Therapeutics (Tianjin) Co., Ltd.* (艾斯拓康生物醫藥(天津)有限公司) from July 2021 to December 2022 and served as vice president of non-clinical research and development. Prior to that, Mr. Zhu worked at Pfizer Inc from 2011 to 2021.

Mr. Zhu obtained his bachelor’s degree in pharmacy from Shenyang Pharmaceutical University* (沈陽藥科學), the PRC, in June 2001. He received his master’s degree in neuropharmacology from the University of British Columbia, Canada, in June 2006. In June 2012, he earned his doctor of philosophy in immunopharmacology and toxicology from the University of Toronto, Canada.

JOINT COMPANY SECRETARIES

The Company has appointed Mr. ZHANG Wendong and Ms. WONG Mei Fung Carrie as our joint company secretaries. For the biographical details of Mr. ZHANG Wendong, please refer to the paragraphs headed “— Board of Directors” in this section.

Ms. WONG Mei Fung Carrie will be appointed as our joint company secretary effective upon [REDACTED].

Ms. Wong has over 20 years of experience in company secretarial and corporate governance fields and is currently a Manager, Entity Solutions at Computershare Hong Kong Investor Services Limited. She obtained a Bachelor of Arts Degree in Accounting and Finance from Edinburgh Napier University. She is a fellow member of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom.

DIRECTORS AND SENIOR MANAGEMENT

BOARD COMMITTEES

Our Company has established three Board Committees in accordance with the relevant PRC laws and regulations, the Articles and the corporate governance practice under the Listing Rules, namely the Audit Committee, the Remuneration Committee and the Nomination Committee.

Audit Committee

The Audit Committee is tasked with overseeing our Company’s financial reporting processes, internal controls, and risk management systems. It ensures the integrity of the Company’s financial statements and compliance with applicable laws and regulations. The Audit Committee comprises three Directors, including Mr. QIAN Junfeng (錢俊峰), Dr. XU Aimin (徐愛民), and Dr. SHI Wei (施維). Mr. Qian, who holds the appropriate professional qualifications as required under the Listing Rules, serves as the chairperson of the committee. The primary duties include, but not limited to the following:

- Monitoring and reviewing the work of external auditors and ensuring their independence.
- Overseeing the internal audit function and evaluating the effectiveness of internal controls.
- Reviewing our Company’s financial statements and making recommendations to the Board.
- Ensuring compliance with corporate governance practices and regulatory requirements.
- Reviewing and approving connected transactions to ensure fairness and transparency.

Remuneration Committee

The Remuneration Committee is responsible for establishing a transparent and fair remuneration framework for the Directors and senior management. The committee ensures that the remuneration policies align with our Company’s performance and strategic goals. The Remuneration Committee comprises three Directors, including Dr. SHI Wei (施維), Dr. CHEN, and Dr. XU Aimin (徐愛民). Dr. SHI Wei serves as the chairperson of the committee. The primary duties include, but not limited to, the following:

- Reviewing and recommending the remuneration packages, bonuses, and other compensation for Directors and senior management.
- Establishing performance evaluation standards and conducting annual performance appraisals for Directors and senior management.
- Ensuring that no Director or any of their associates is involved in determining their own remuneration.
- Monitoring the implementation of our Company’s remuneration policies, including share-based compensation schemes.
- Reviewing and approving matters related to share schemes under Chapter 17 of the Listing Rules.

Nomination Committee

The Nomination Committee is responsible for ensuring that the Board has a balanced composition of skills, experience, and diversity to effectively oversee our Company’s operations. The Nomination Committee consists of three Directors, including Dr. XU Aimin (徐愛民), Ms. CHEN Mingxia (陳明俠), and Dr. SHI Wei (施維). Dr. XU Aimin serves as the chairperson of the committee. The primary duties include, but not limited to the following:

- Reviewing the structure, size, and composition of the Board to ensure diversity and alignment with our Company’s strategic needs.
- Identifying and recommending individuals suitably qualified to become Directors or senior management.
- Evaluating the independence of independent non-executive Directors.

DIRECTORS AND SENIOR MANAGEMENT

- Overseeing Board succession planning to ensure continuity in leadership.
- Formulating and implementing policies related to Board diversity and disclosing progress in achieving diversity objectives.

BOARD DIVERSITY POLICY

Our Company recognises and embraces the importance of board diversity as a key driver of effective decision-making and corporate governance. To this end, we have adopted a board diversity policy that sets out the objective and approach to achieving and maintaining diversity at the Board level. This policy is designed to ensure that the Board benefits from a broad range of perspectives, skills, and experiences, which are essential for the sustainable growth of our Company. Pursuant to our board diversity policy, we seek to achieve Board diversity through the consideration of a number of factors, including but not limited to gender, age, race, educational background, cultural background and professional experience.

We remain committed to promoting gender diversity across all levels of our Company, particularly within the Board and senior management. This includes maintaining at least one female Director and ensuring female representation on the Nomination Committee at all times. We will actively encourage the recommendation of female board candidates and expose promising mid to senior level staff to Board meetings to cultivate a pipeline of future directors. Furthermore, we emphasize gender diversity in mid to senior level recruitment and provide targeted training and long-term development opportunities for female talent in areas such as operations, management, finance, and legal compliance. These efforts will ensure a sustainable pool of qualified female candidates for future Board nominations and senior leadership roles.

Our Directors have a mixed of knowledge and skills, including but not limited to biochemistry, accounting and corporate governance. Furthermore, our Board consist of eight male members and one female member, with ages ranging from 39 to 66, and who have diverse experience in business management, biopharmaceutical R&D, clinical development, legal, finance and accounting. Our Company has reviewed the membership, structure and composition of our Board, and is of the opinion that the structure of our Board is reasonable, and the experience and skills of the Directors in various aspects and fields can enable our Company to maintain a high standard of operation.

REMUNERATION OF DIRECTORS AND SENIOR MANAGEMENT

We offer our executive Directors, who are also our Company’s employees, compensation in the form of salaries, discretionary bonus, share-based payment, social welfare and other benefits in kind. Our independent non-executive Directors receive compensation with reference to their respective positions and duties, including being a member or the chairperson of Board committees. For the two years ended December 31, 2025 and the six months ended June 30, 2026, the aggregate amount of remuneration paid, including share-based compensation, to our Directors amounted to RMB2,027,000, RMB2,774,000, and RMB3,440,000, respectively.

The remuneration of our Directors was determined with reference to factors including but not limited to the responsibility, risk and commitment of our Directors and senior management, the performance evaluation structure and results and the salaries paid by comparable companies.

The aggregate remuneration of the five highest-paid employees (who were neither a director nor chief executive of the Company) for the two years ended December 31, 2025 and the six months ended June 30, 2026 amounted to RMB5,744,000, RMB5,579,000, and RMB1,528,000, respectively.

It is estimated that remuneration is equivalent to approximately RMB8,604,011 in aggregate paid to the Directors and members of senior management by our Company for the year ended December 31, 2026.

No remuneration was paid by the Company to the Directors, members of senior management or the five highest paid individuals as an inducement to join or upon joining the Company or as compensation for loss of office during the Track Record Period. Furthermore, none of the Directors had

DIRECTORS AND SENIOR MANAGEMENT

waived or agreed to waive any remuneration during the Track Record Period. Save as disclosed above, no other payments have been paid, or are payable, by our Company to our Directors or the five highest-paid individuals during the Track Record Period.

CORPORATE GOVERNANCE CODE

Our Company is committed to achieving high standards of corporate governance with a view to safeguarding the interests of our Shareholders. To accomplish this, our Company intends to comply with Corporate Governance Code set out in Appendix C1 to the Listing Rules and the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Listing Rules after the [REDACTED].

DEVIATION FROM CORPORATE GOVERNANCE CODE

Pursuant to code provision C.2.1 in the Corporate Governance Code as set out in Appendix C1 to the Listing Rules, the roles of chairman and chief executive should be separate and should not be performed by the same individual.

Dr. CHEN is currently serving as the chairman of our Board, executive Director, and chief executive officer (who is responsible under the immediate authority of the Board for the conduct of the business of the Company). Dr. CHEN is a founder of our Group and has been primarily involved in overall strategic planning and development of our Group and overall operation of our Group. Our Directors consider that vesting the roles of both the chairman of the Board and the chief executive officer of the Company in Dr. CHEN is beneficial to the business prospects of the Group by ensuring consistent leadership to the Group as well as prompt and effective decision-making and implementation. In addition, our Directors believe that this structure will not impair the balance of power and authority between the Board and the management of the Company, given that: (i) decision to be made by our Board requires approval by at least a majority of our Directors; (ii) Dr. CHEN and the other Directors are aware of and undertake to fulfill their fiduciary duties as Directors, which require, among other things, that he acts for the benefit and in the best interests of our Company and will make decisions for our Company accordingly; (iii) the balance of power and authority is ensured by the operations of the Board and the senior management in accordance with the Listing Rules, the Articles and other applicable laws and regulations; and (iv) the overall strategic and other key business, financial, and operational policies of our Company are made collectively after thorough discussion at both the Board, and senior management levels.

We will continue to review our corporate governance policies and compliance with the Listing Rules and will adhere to the relevant principles as set out in the Corporate Governance Code after the [REDACTED].

COMPLIANCE ADVISOR

We have appointed Halcyon Capital Limited as our compliance adviser pursuant to Rule 3A.19 of the Listing Rules. Pursuant to Rule 3A.23 of the Listing Rules and the terms of engagement, the Compliance Advisor will advise our Company in certain circumstances including:

- before the publication of any regulatory announcement, circular or financial report;
- where a transaction, which might be a notifiable or connected transaction, is contemplated including share issues, sales or transfers of treasury shares and share repurchases;
- where our Company proposes to use the [REDACTED] of the [REDACTED] in a manner different from that detailed in this Document or where the business activities, developments or results of the [REDACTED] deviate from any forecast, estimate, or other information in this Document; and
- where the Hong Kong Stock Exchange makes an inquiry to our Company regarding unusual movements in the price or [REDACTED] of our Company's [REDACTED] Shares, the possible development of a false market in its securities, or any other matters in accordance with Rule 13.10 of the Listing Rules.

Pursuant to Rule 3A.24 of the Listing Rules, Halcyon Capital Limited will, in a timely manner, inform us of any amendment or supplement to the Listing Rules and new or amended laws and regulations in Hong Kong applicable to us.

The term of the appointment will commence on the date of [REDACTED] of the Shares and is expected to end on the date on which we distribute our financial results for the first full financial year commencing after the date of its [REDACTED].